You are here

TOPIC 313 PHASE I; RNAI CANCER THERAPEUTICS USING NANOTECHNOLOGY; HHSN2612013000

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: N43CA130030
Agency Tracking Number: N43CA130030
Amount: $200,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: N/A
Timeline
Solicitation Year: 2013
Award Year: 2013
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
GENESEGUES, INC. 3180 HIGH POINT DRIVE
CHASKA, MN 55318-9476
United States
DUNS: 95972415
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 GRETCHEN UNGER
 (952) 443-3798
 GMU@GENESEGUES.COM
Business Contact
 GRETCHEN UNGER
Phone: (952) 443-3798
Email: GMU@GENESEGUES.COM
Research Institution
 Stub
Abstract

The design, fabrication, characterization, and preclinical evaluation of novel nanoparticle-based drug formulations capable of delivering candidate RNAi therapeutics for the treatment of cancer. PUBLIC HEALTH RELEVANCE

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government